Everand Logo

Welcome to Everand!

  • STAT

    Christi Shaw, inspired by her sister’s cancer, named CEO of Kite Pharma, Gilead’s anti-cancer unit

    Christi Shaw, an Eli Lilly executive, has been named the new head of Kite Pharma, which is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.
    by Matthew Herper Jul 11, 2019 2 minutes

    Christi Shaw, until Thursday morning the executive in charge of Eli Lilly’s drug division, will become the CEO of Kite Pharma, the unit of biotechnology giant Gilead that is focused on treatments that genetically engineer patients’ white blood cells to attack cancer.

    Shaw said she was inspired to take the job because that type of treatment, known as CAR-T, is what she wants to focus

    You’re reading a preview, subscribe to read more.

    More from STAT

    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About Sanofi Licensing Novavax’s Covid Shot, Moderna’s RSV Vaccine, And More
    Sanofi said it has reached a licensing deal to sell Novavax’s Covid shot as well as to try to combine the vaccine with Sanofi’s own flu vaccine.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About BIO’s China Challenge, Zepbound Shortages, And More
    BIO's about-face in its relationship with WuXi AppTec illustrates the difficulty the biotech industry faces in dealing with an issue that is moving fast and forcefully.
    STAT2 min read
    STAT+: Pharmalittle: We’re Reading About A Boy Dying In Pfizer Trial; AstraZeneca Yanking Covid Shot, And More
    A young boy died in a clinical trial for an experimental Pfizer gene therapy for Duchenne muscular dystrophy, about a year after receiving the therapy.

    Related Books & Audiobooks